Influenza Articles
The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee chose the Northern Hemisphere’s 2018-19 influenza (flu) vaccine strains based on the World Health Organization’s recommendations.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has updated its 2017-18 recommendations regarding the use of seasonal influenza (flu) vaccines and guidance for vaccine providers about the use of flu vaccines for the 2018-19 season.
FDA's Vaccines and Related Biological Products Advisory Committee chose the Northern Hemisphere’s 2018-19 influenza (flu) vaccine strains based on the World Health Organization’s recommendations.
The Centers for Disease Control and Prevention advisory committee has voted 12-2 to recommend FluMist, the nasal spray version of the influenza vaccine, be used during the 2018-19 influenza (flu) season.
Japanese drug maker Shionogi has created an experimental compound delivered via a single-dose pill that has been shown to effectively kill the influenza (flu) virus in patients within a single day.
Researchers at the University of Oxford have begun a two-year clinical trial to test a universal influenza (flu) vaccine in more than 2,000 patients.
With many reports about this year’s influenza (flu) vaccine ineffectiveness, a new study shows it is more effective than thought, especially among children.
Scientists at the National Institutes of Health, Frederick National Laboratory for Cancer Research and the University of Melbourne in Australia tested a new universal flu vaccine that produced good immunity against several different strains of influenza viruses.
Researchers at the University of Nottingham in England have found evidence that being in a positive mood when receiving an influenza (flu) vaccine can increase its protective effect.
In an effort to understand how current influenza vaccines are influenced by preexisting immunity in people of different ages, researchers vaccinated volunteers ages 18 years to 85 years with split, inactivated Fluzone influenza vaccine in four consecutive seasons from 2013 to 2016, and assessed the impact of repeated vaccination on breadth and durability of antibodies as a result of vaccine strain changes.
A new study conducted by the Centers for Disease Control and Prevention shows that during the years 2010 through 2014, the influenza vaccine reduced the risk of flu-associated death by half among children with underlying high-risk medical conditions and by nearly two-thirds among healthy children.
Study results from the division of oncology at University Hospital Basel in Switzerland show that patients treated with PD-1/PD-L1 checkpoint inhibitors may be at an increased risk for adverse events after receiving the seasonal influenza vaccination.
